KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges (2018 - 2022)

TherapeuticsMD (TXMD) has disclosed Amortization of Deferred Charges for 8 consecutive years, with $3.1 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Amortization of Deferred Charges rose 108.67% year-over-year to $3.1 million, compared with a TTM value of $21.6 million through Sep 2022, up 327.83%, and an annual FY2021 reading of $5.7 million, up 124.68% over the prior year.
  • Amortization of Deferred Charges was $3.1 million for Q3 2022 at TherapeuticsMD, down from $7.9 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $9.0 million in Q1 2022 and bottomed at $119754.0 in Q3 2018.
  • Average Amortization of Deferred Charges over 5 years is $1.7 million, with a median of $372000.0 recorded in 2020.
  • The sharpest move saw Amortization of Deferred Charges plummeted 45.33% in 2020, then soared 915.91% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $119950.0 in 2018, then skyrocketed by 127.74% to $273171.0 in 2019, then surged by 224.71% to $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then surged by 101.31% to $3.1 million in 2022.
  • Business Quant data shows Amortization of Deferred Charges for TXMD at $3.1 million in Q3 2022, $7.9 million in Q2 2022, and $9.0 million in Q1 2022.